Rethinking bone quality after FDA qualification of total hip BMD as a surrogate endpoint.

Kawaguchi H

Open source

DOI
10.1016/j.bonr.2026.101968
Published
2026 Dec
Container
Bone reports
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.bonr.2026.101968,
  title = {Rethinking bone quality after FDA qualification of total hip BMD as a surrogate endpoint.},
  author = {Kawaguchi H},
  year = {2026},
  journal = {Bone reports},
  doi = {10.1016/j.bonr.2026.101968},
  url = {https://doi.org/10.1016/j.bonr.2026.101968}
}

RIS

TY  - JOUR
TI  - Rethinking bone quality after FDA qualification of total hip BMD as a surrogate endpoint.
AU  - Kawaguchi H
PY  - 2026
JO  - Bone reports
DO  - 10.1016/j.bonr.2026.101968
UR  - https://doi.org/10.1016/j.bonr.2026.101968
ER  - 

APA

H, K. (2026). Rethinking bone quality after FDA qualification of total hip BMD as a surrogate endpoint.. Bone reports. https://doi.org/10.1016/j.bonr.2026.101968

Source records